ASCO recently held its 2025 conference from May 30-June 3, 2025. Click the links below to read about MBC-related reports from this meeting.
Overview of MBC Results
- Living Beyond Breast Cancer (webinar): Nan Chen, MD, gives updates about MBC clinical trials from the 2025 ASCO annual meeting
General Results for People with MBC
- Breastcancer.org: Paclitaxel (Taxol®) by mouth works just as well as when it is given by IV and is also less likely to cause neuropathy (scroll to “Oral paclitaxel seems…”)
Results for People with Hormone Receptor-Positive (HR+), HER2-Negative (HER2-) MBC
- Breastcancer.org: In people with PIK3CA-mutated HR+, HER2- hormone therapy-resistant MBC, adding the PI3K pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance®) and fulvestrant (Faslodex®) improved survival and delayed the need for chemotherapy by almost 2 years (scroll to “Adding inavolisib…”)
- Living Beyond Breast Cancer: Survival is longer when switching from an aromatase inhibitor to the experimental SERD (drug that breaks down estrogen receptors) camizestrant when an ESR1 mutation is detected with liquid biopsy before disease progression is seen on a scan
- Breastcancer.org: The experimental PROTAC SERD (drug that causes the cell to break down estrogen receptors) vepdegestrant provides longer survival than fulvestrant (Faslodex®) (scroll to “New oral SERD beats Faslodex…”)
Results for People with HER2-Positive (HER2+) MBC
- Breastcancer.org: The combination of trastuzumab deruxtecan (T-DXd; Enhertu®) and pertuzumab (Perjeta®) in the first line provides longer survival than standard of care (a taxane chemotherapy with trastuzumab (Herceptin®) and pertuzumab (Perjeta®)) in people with HER2+ MBC (scroll to “Metastatic HER2-positive breast cancer may have new first treatment”)
- Healio: Artifical intelligence (AI) may improve the accuracy of detecting HER2-low and HER2-ultralow breast cancer
Results for People with Triple-Negative MBC
- Breastcancer.org: Sacituzumab govitecan (Trodelvy®) with pembrolizumab (Keytruda®) led to longer survival than pembrolizumab (Keytruda®) with chemotherapy in triple-negative MBC and may become a new standard of care (scroll to “Trodelvy plus Keytruda outperforms…”)